Term
|
Definition
| 30s ribosomal bacteriostatics; anaerobes, rickettsia, chlamydia, mycoplasmas; complete cross-resistance; absorption impaired by dairy, iron, calcium; GI effects, photosensitivity, superinfections, renal toxicity, bone/teeth; |
|
|
Term
|
Definition
| 50s ribosomal bacteriostatic; gram negative bacts (H. influenzae, salmonella, neisseria, B. fragilis); gray baby syndrome, ir/reversible anemias; |
|
|
Term
|
Definition
| 30s ribosomal bacteriostatic; extracellular space; serious gram negative bacts (E. coli, klebsiella, proteus, enterobacter, pseudomonas); IV; neuro-/nephro-toxicity, neuromuscular block; inactivates penicillins/other nephrotoxins; |
|
|
Term
|
Definition
| 50s ribosomal bacteriostatics; upper respiratory (bordetella, legionella, chlamydiae, mycoplasma, rickettsia); GI irritation, P450(CYP) metabolism; clarithromycin (PLUS mycobacterium avium, H. pylori); azithromycin (AND H. influenzae, chlamydiae) |
|
|
Term
|
Definition
| PABA congener; short t1/2, very soluble, NO CSF; uncomplicated UTI |
|
|
Term
|
Definition
| PABA congener; short t1/2, more risk of crystalluria |
|
|
Term
|
Definition
| PABA congener; highest [CSF]; brisk, alkaline urine to prevent crystalluria |
|
|
Term
|
Definition
| PABA congener; poorly absorbed prodrug, good for bowel; anti-inflammatory; possible systemic toxicity |
|
|
Term
|
Definition
| PABA congener; anti-fungal/bacterial; topical, serious burns |
|
|
Term
|
Definition
| PABA congener; eye drop/topical; chlamydia; neutral at [high] |
|
|
Term
|
Definition
| acetylated in liver; require renal monitoring; crystalluria risk; hypersensitivity (Stevens-Johnson syndrome); |
|
|
Term
| Trimethoprim-Sulfamethoxazole |
|
Definition
| PABA congener AND tetrahydrofolate inhibitor; anti-fungal/bacterial; 12 organisms (gram negative rods, actinomycetes, parasites, Pneumocytis jirovecii); AIDS infections; harder to resist (2 drugs); glossitis, crystalluria, hypersensitivity, folate deficiency |
|
|
Term
|
Definition
| ammonia, formaldehyde; pH<5.5; no resistance; gastric/liver effects; crystalluria with sulfa; gout with organic acid; |
|
|
Term
|
Definition
| toxic by-products; uncomplicated UTI; enterococcus, e. coli; GI effects, pulmonary/hepato-toxicity, neuropathy, brown urin |
|
|
Term
|
Definition
| blocks cell wall peptidoglycans; single dose = 3 days; gram negative, NOT pseudomonas; |
|
|
Term
|
Definition
| analgesic; urine excretion; stains |
|
|
Term
|
Definition
| 1st gen. fluoroquinolone; bacteriacidal, topoisomerase II, IV; NO spirochetes, anaerobes; oral admin, safe; |
|
|
Term
|
Definition
| 1st gen. fluoroquinolone; once daily; bronchitis, pneumococci; |
|
|
Term
| Second generation fluoroquinolones |
|
Definition
| oral once daily; gemi-/levo-/moxi-floxacin |
|
|
Term
|
Definition
| TB, prophylaxis; peripheral neuritis, hepatitis |
|
|
Term
|
Definition
| TB; jaundice, red-orange secretions, hepatic effects |
|
|
Term
|
Definition
| TB; visual acuity effects, gout |
|
|
Term
| Streptomycin, Pyrazidimine |
|
Definition
| TB; liver necrosis, gout, GI effects |
|
|
Term
|
Definition
| alternate to penicillin, anaerobic infections |
|
|
Term
|
Definition
| kills methicillin resistant staph |
|
|
